MA71321A - Anticorps bispécifiques anti-pcrv et psl pour le traitement de la bronchiectasie - Google Patents
Anticorps bispécifiques anti-pcrv et psl pour le traitement de la bronchiectasieInfo
- Publication number
- MA71321A MA71321A MA71321A MA71321A MA71321A MA 71321 A MA71321 A MA 71321A MA 71321 A MA71321 A MA 71321A MA 71321 A MA71321 A MA 71321A MA 71321 A MA71321 A MA 71321A
- Authority
- MA
- Morocco
- Prior art keywords
- pcrv
- bronchiectasis
- treatment
- bispecific anti
- psl antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/1214—Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263367309P | 2022-06-29 | 2022-06-29 | |
| PCT/EP2023/067575 WO2024003103A1 (fr) | 2022-06-29 | 2023-06-28 | Anticorps bispécifiques anti-pcrv et psl pour le traitement de la bronchiectasie |
| EP23738427.6A EP4547712A1 (fr) | 2022-06-29 | 2023-06-28 | Anticorps bispécifiques anti-pcrv et psl pour le traitement de la bronchiectasie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71321A true MA71321A (fr) | 2025-04-30 |
Family
ID=87155664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71321A MA71321A (fr) | 2022-06-29 | 2023-06-28 | Anticorps bispécifiques anti-pcrv et psl pour le traitement de la bronchiectasie |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250382356A1 (fr) |
| EP (1) | EP4547712A1 (fr) |
| JP (1) | JP2025521777A (fr) |
| KR (1) | KR20250044668A (fr) |
| CN (1) | CN119546631A (fr) |
| AU (1) | AU2023300231A1 (fr) |
| CA (1) | CA3260770A1 (fr) |
| IL (1) | IL318036A (fr) |
| MA (1) | MA71321A (fr) |
| TW (1) | TW202417478A (fr) |
| WO (1) | WO2024003103A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025231041A1 (fr) * | 2024-04-30 | 2025-11-06 | Renovion, Inc. | Méthodes de réduction de symptômes chez des sujets souffrant de bronchiectasie et d'autres maladies pulmonaires |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690935A3 (fr) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Génération d'anticorps xenogéniques |
| WO2013070615A1 (fr) | 2011-11-07 | 2013-05-16 | Medlmmune, Llc. | Polythérapies utilisant des molécules de liaison anti-psl et pcrv de pseudomonas |
| US20150284450A1 (en) | 2012-11-06 | 2015-10-08 | Medimmune, Llc | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
| US20170183397A1 (en) | 2014-05-05 | 2017-06-29 | Medimmune, Llc | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
| HK1257193A1 (zh) * | 2015-11-30 | 2019-10-18 | Medimmune Limited | 用於预防或治疗医源性肺炎的方法 |
-
2023
- 2023-06-28 IL IL318036A patent/IL318036A/en unknown
- 2023-06-28 MA MA71321A patent/MA71321A/fr unknown
- 2023-06-28 JP JP2024577079A patent/JP2025521777A/ja active Pending
- 2023-06-28 KR KR1020257002568A patent/KR20250044668A/ko active Pending
- 2023-06-28 WO PCT/EP2023/067575 patent/WO2024003103A1/fr not_active Ceased
- 2023-06-28 TW TW112124123A patent/TW202417478A/zh unknown
- 2023-06-28 CN CN202380050910.8A patent/CN119546631A/zh active Pending
- 2023-06-28 EP EP23738427.6A patent/EP4547712A1/fr active Pending
- 2023-06-28 AU AU2023300231A patent/AU2023300231A1/en active Pending
- 2023-06-28 US US18/878,285 patent/US20250382356A1/en active Pending
- 2023-06-28 CA CA3260770A patent/CA3260770A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3260770A1 (fr) | 2024-01-04 |
| AU2023300231A1 (en) | 2025-02-13 |
| KR20250044668A (ko) | 2025-04-01 |
| IL318036A (en) | 2025-02-01 |
| US20250382356A1 (en) | 2025-12-18 |
| WO2024003103A1 (fr) | 2024-01-04 |
| EP4547712A1 (fr) | 2025-05-07 |
| CN119546631A (zh) | 2025-02-28 |
| JP2025521777A (ja) | 2025-07-10 |
| TW202417478A (zh) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3920889A4 (fr) | Exosomes contenant de la télomérase pour le traitement de maladies associées au vieillissement et à un dysfonctionnement d'organe lié à l'âge | |
| MA71708A (fr) | Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 | |
| EP3414573A4 (fr) | Nouveaux anticorps monoclonaux anti-lam et anti-pim6/lam pour le diagnostic et le traitement d'infections par le bacille de koch | |
| EP4297871A4 (fr) | Procédés et compositions pour le traitement de l'agitation | |
| MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| EP3573658A4 (fr) | Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif | |
| MA52961A (fr) | Compositions et procédés pour la réduction ou le traitement d'une inflammation | |
| EP4054589A4 (fr) | Procédés de traitement de l'éosophagite à éosinophiles et de réduction de la candidose | |
| EP4138906A4 (fr) | Méthodes pour la prophylaxie et le traitement de la covid et de la covid-19 | |
| MA48751A (fr) | Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax | |
| MA54525A (fr) | Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie | |
| EP4139364A4 (fr) | Anticorps bispécifiques pour le traitement de maladies associées à cd47 | |
| MA55872A (fr) | Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires | |
| EP4423116A4 (fr) | Procédés et compositions pour le traitement du glioblastome | |
| EP3880709A4 (fr) | Schéma posologique d'un anticorps anti-lag3 et polythérapie avec un anticorps anti-pd-1 pour le traitement du cancer | |
| EP3727374A4 (fr) | Association d'un anticorps anti-pd-l1 et d'un inhibiteur de l'ido1 pour le traitement du cancer | |
| EP4351610A4 (fr) | Procédé et composition pour la prévention et le traitement de la covid-19 et de la covid longue | |
| EP4099997A4 (fr) | Méthodes et compositions pour le traitement de maladies | |
| EP3500282A4 (fr) | Composition anti-inflammatoire pour le traitement d'une inflammation articulaire aiguë et son procédé de préparation | |
| EP4097137A4 (fr) | Combinaisons d'inhibiteurs d'egfr et d'inhibiteurs de ror1 pour le traitement du cancer | |
| EP4340881A4 (fr) | Anticorps pour le traitement d'alpha-synucléinopathies | |
| EP4210750A4 (fr) | Méthodes et agents thérapeutiques pour le traitement d'un infarctus du myocarde | |
| CA3249951A1 (fr) | Compositions pharmaceutiques pour le traitement de la douleur | |
| MA71376A (fr) | Produit de fermentation pour le traitement de maladies inflammatoires |